Roche Holding AG Message Board
-
"The biggest news in today's press release, given that approval was expected, was that the label allows for "The biggest news in today's press release, given that approval was expected, was that the label allows for use in front-line HER-2 positive metastatic breast cancer," says Cowen's Simos Simeonidis in a note.
Sentiment: Strong Buy
-
"This was not a major surprise, since EMILIA included about 12% front-line mBC patients (about 60 1st-line mBC patients in the T-DM1 arm of the EMILIA trial), but it was definitely not a given."
-
The date on the report is 3/30/13.
S&P rates it 5 stars with a Strong Buy.
It has a 12 month price target of $17.00Sentiment: Strong Buy
-
With all of the AACR presentations it'll be
a nice BOOST for the industry IMO.
The address is posted over on IV #35899
GLTA -
"The biggest news in today's press release, given that approval was expected, was that the label allows for use in front-line HER-2 positive metastatic breast cancer," says Cowen's Simos Simeonidis in a note this This morning -- "This was not a major surprise, since EMILIA included about 12% front-line mBC patients (about 60 1st-line mBC patients in the T-DM1 arm of the EMILIA trial), but it was definitely not a given."